CR20140549A - Formas cristalinas de un modulador del receptor androgénico - Google Patents

Formas cristalinas de un modulador del receptor androgénico

Info

Publication number
CR20140549A
CR20140549A CR20140549A CR20140549A CR20140549A CR 20140549 A CR20140549 A CR 20140549A CR 20140549 A CR20140549 A CR 20140549A CR 20140549 A CR20140549 A CR 20140549A CR 20140549 A CR20140549 A CR 20140549A
Authority
CR
Costa Rica
Prior art keywords
androgenic
crystal forms
receiver modulator
modulator
receiver
Prior art date
Application number
CR20140549A
Other languages
English (en)
Inventor
Nicholas D Smith
Mark R Herbert
Ouathek Ouerfelli
Anna Dilhas
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140549(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer filed Critical Aragon Pharmaceuticals Inc
Publication of CR20140549A publication Critical patent/CR20140549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente descripción se describe formas amorfas y cristalinas del modulador del receptor androgénico 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida.
CR20140549A 2012-06-07 2014-12-01 Formas cristalinas de un modulador del receptor androgénico CR20140549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
CR20140549A true CR20140549A (es) 2015-04-06

Family

ID=49712550

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20190331A CR20190331A (es) 2012-06-07 2013-06-04 UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)
CR20140549A CR20140549A (es) 2012-06-07 2014-12-01 Formas cristalinas de un modulador del receptor androgénico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20190331A CR20190331A (es) 2012-06-07 2013-06-04 UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)

Country Status (45)

Country Link
US (10) US9481663B2 (es)
EP (4) EP3533792B1 (es)
JP (3) JP6182209B2 (es)
KR (2) KR102195916B1 (es)
CN (3) CN105693692A (es)
AU (3) AU2013271751B2 (es)
BR (1) BR112014030678A2 (es)
CA (4) CA2875767C (es)
CL (1) CL2014003331A1 (es)
CO (1) CO7240407A2 (es)
CR (2) CR20190331A (es)
CY (4) CY1120393T1 (es)
DK (3) DK3348553T3 (es)
EA (3) EA028791B1 (es)
EC (1) ECSP14030098A (es)
ES (3) ES2670683T3 (es)
FR (1) FR21C1050I2 (es)
GT (1) GT201400283A (es)
HK (2) HK1210175A1 (es)
HR (3) HRP20180902T1 (es)
HU (4) HUE050357T2 (es)
IL (5) IL320522A (es)
IN (1) IN2014DN10084A (es)
LT (4) LT2858985T (es)
LU (1) LUC00236I2 (es)
ME (2) ME03815B (es)
MX (1) MX356754B (es)
MY (1) MY187500A (es)
NI (1) NI201400142A (es)
NL (1) NL301144I2 (es)
NO (1) NO2021046I1 (es)
NZ (2) NZ702203A (es)
PE (3) PE20200795A1 (es)
PH (2) PH12014502714B1 (es)
PL (3) PL2858985T3 (es)
PT (3) PT2858985T (es)
RS (3) RS60617B1 (es)
SG (3) SG10201610248SA (es)
SI (3) SI3348553T1 (es)
SM (3) SMT201800311T1 (es)
TR (1) TR201808939T4 (es)
TW (1) TWI532732B (es)
UA (2) UA115665C2 (es)
WO (1) WO2013184681A1 (es)
ZA (1) ZA201500076B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
RS60617B1 (sr) * 2012-06-07 2020-09-30 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
DK2945628T3 (da) * 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
CN106795152B (zh) * 2014-08-26 2020-01-31 安斯达尔生物技术有限责任公司 蛋白激酶抑制剂
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions
EA201791222A1 (ru) * 2014-12-05 2017-09-29 Арагон Фармасьютикалз, Инк. Противораковые композиции
HUE051888T2 (hu) 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
MX2017008050A (es) 2014-12-19 2018-01-18 Lutron Electronics Co Accesorio de iluminacion multicanal que tiene controladores de diodo emisor de luz.
JP2019517497A (ja) 2016-06-03 2019-06-24 アラゴン ファーマシューティカルズ，インコーポレイテッド 抗癌性組成物
US11149017B2 (en) 2016-12-13 2021-10-19 Watson Laboratories Inc. Solid state forms of apalutamide
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019242439A1 (zh) * 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4541786A3 (en) 2020-09-04 2025-08-06 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
SG10201907588XA (en) 2010-02-16 2019-09-27 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
RS60617B1 (sr) * 2012-06-07 2020-09-30 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Also Published As

Publication number Publication date
CY2021032I2 (el) 2022-03-24
HK1226066A1 (zh) 2017-09-22
HUE038082T2 (hu) 2018-09-28
PE20200725A1 (es) 2020-07-21
SI2858985T1 (sl) 2018-12-31
SMT202100355T1 (it) 2021-07-12
US10556882B2 (en) 2020-02-11
US20170001977A1 (en) 2017-01-05
CR20190331A (es) 2019-11-12
CY1124831T1 (el) 2022-03-24
ECSP14030098A (es) 2016-01-29
EP2858985B1 (en) 2018-04-18
EA201992010A1 (ru) 2020-01-24
SG10201610248SA (en) 2017-02-27
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
AU2017200298B2 (en) 2017-09-28
ME03815B (me) 2021-04-20
LT3348553T (lt) 2020-09-25
JP6345821B2 (ja) 2018-06-20
HUE054595T2 (hu) 2021-09-28
PL3348553T3 (pl) 2021-02-08
US20180258067A1 (en) 2018-09-13
LT2858985T (lt) 2018-09-25
US20190241539A1 (en) 2019-08-08
IL267608A (en) 2019-08-29
CY2021032I1 (es) 2022-03-24
IL320522A (en) 2025-06-01
IL267608B1 (en) 2025-06-01
MX356754B (es) 2018-06-11
NZ717683A (en) 2018-04-27
CN104619692A (zh) 2015-05-13
IL275413A (en) 2020-07-30
HUS2100047I1 (hu) 2021-11-29
JP6182209B2 (ja) 2017-08-16
EA201791592A1 (ru) 2018-01-31
SMT201800311T1 (it) 2018-07-17
PT2858985T (pt) 2018-07-10
HRP20201387T1 (hr) 2020-11-27
RS60617B1 (sr) 2020-09-30
JP2015518890A (ja) 2015-07-06
JP2018141009A (ja) 2018-09-13
IL259738B (en) 2021-06-30
CA3114726A1 (en) 2013-12-12
EA028791B1 (ru) 2017-12-29
PE20200795A1 (es) 2020-08-10
EP3348553A1 (en) 2018-07-18
US12018008B2 (en) 2024-06-25
WO2013184681A1 (en) 2013-12-12
IL267608B2 (en) 2025-10-01
UA123142C2 (uk) 2021-02-24
CY1123427T1 (el) 2021-12-31
US9994545B2 (en) 2018-06-12
EP2858985A1 (en) 2015-04-15
EA201492272A1 (ru) 2015-05-29
EA033956B1 (ru) 2019-12-13
CA3055660A1 (en) 2013-12-12
US20250092011A1 (en) 2025-03-20
AU2013271751A1 (en) 2014-12-18
HRP20210909T1 (hr) 2021-09-03
PT3533792T (pt) 2021-06-07
US10766875B2 (en) 2020-09-08
TW201402561A (zh) 2014-01-16
CA3008345C (en) 2019-10-22
TR201808939T4 (tr) 2018-07-23
CA3008345A1 (en) 2013-12-12
PH12016501470A1 (en) 2017-07-10
PH12014502714A1 (en) 2015-02-02
LUC00236I2 (es) 2025-02-03
AU2017279807A1 (en) 2018-01-25
EP3348553B1 (en) 2020-07-08
TWI532732B (zh) 2016-05-11
ES2809738T3 (es) 2021-03-05
PT3348553T (pt) 2020-09-28
KR20190132543A (ko) 2019-11-27
EP2858985A4 (en) 2016-05-25
US9481663B2 (en) 2016-11-01
KR20150021993A (ko) 2015-03-03
CL2014003331A1 (es) 2016-03-04
US20200354335A1 (en) 2020-11-12
LTPA2021525I1 (es) 2021-11-25
EP3533792B1 (en) 2021-05-05
US20150133481A1 (en) 2015-05-14
FR21C1050I2 (fr) 2024-05-24
LTC3533792I2 (es) 2024-07-10
US10308630B2 (en) 2019-06-04
SI3533792T1 (sl) 2021-11-30
AU2013271751B2 (en) 2017-02-23
NL301144I2 (nl) 2025-03-20
ES2670683T3 (es) 2018-05-31
CO7240407A2 (es) 2015-04-17
CN113135892A (zh) 2021-07-20
SG11201408140QA (en) 2015-01-29
EP3533792A1 (en) 2019-09-04
RS61988B1 (sr) 2021-07-30
ME03081B (me) 2019-01-20
HRP20180902T1 (hr) 2018-08-24
US20200115361A1 (en) 2020-04-16
NO2021046I1 (no) 2021-11-02
UA115665C2 (uk) 2017-12-11
US20210163441A1 (en) 2021-06-03
DK3533792T3 (da) 2021-06-28
PH12016501470B1 (en) 2021-12-10
FR21C1050I1 (fr) 2021-12-10
KR102195916B1 (ko) 2020-12-30
SG10201610249TA (en) 2017-02-27
US20260109683A1 (en) 2026-04-23
HK1210175A1 (en) 2016-04-15
GT201400283A (es) 2017-07-03
MY187500A (en) 2021-09-24
HUE050357T2 (hu) 2020-11-30
PL3533792T3 (pl) 2021-11-29
PH12014502714B1 (en) 2015-02-02
NZ702203A (en) 2016-09-30
CN105693692A (zh) 2016-06-22
EP3922629A1 (en) 2021-12-15
JP2017178923A (ja) 2017-10-05
IL236055A0 (en) 2015-02-01
PL2858985T3 (pl) 2018-09-28
SI3348553T1 (sl) 2020-11-30
BR112014030678A2 (pt) 2017-06-27
DK3348553T3 (da) 2020-07-27
AU2017279807B2 (en) 2018-11-08
US10526310B2 (en) 2020-01-07
PE20150631A1 (es) 2015-05-11
IL259738A (en) 2018-07-31
US20190330182A1 (en) 2019-10-31
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
LT3533792T (lt) 2021-07-26
MX2014015005A (es) 2015-09-04
IN2014DN10084A (es) 2015-08-21
CA2875767A1 (en) 2013-12-12
RS57370B1 (sr) 2018-08-31
ZA201500076B (en) 2016-10-26
CA2875767C (en) 2018-08-14
CY1120393T1 (el) 2019-07-10
AU2017200298A1 (en) 2017-02-02
DK2858985T3 (en) 2018-05-28
ES2875932T3 (es) 2021-11-11

Similar Documents

Publication Publication Date Title
PH12016500968B1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
GT201400283A (es) Formas cristalinas de un modulador del receptor androgénico
ZA201508207B (en) Phakic lens device with openings and concentric annular zones
EP2859741A4 (en) RECEPTION IN REST MODE FOR GROUP COMMUNICATION ON LTE EMBMS
EP3039015A4 (en) Substituted pyrimidine bmi-1 inhibitors
CL2015002616A1 (es) 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina.
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
MY172739A (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL243092A0 (en) New triazolo[d–4,5]pyrimidine histories
PH12014502269A1 (en) Anti-fgfr2 antibody
EP3073870A4 (en) Hip seat carrier set
IN2015KN00365A (es)
EP3027619A4 (en) Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
IL231337A (en) Optical receiver and transmitter - receiver that uses it
UY34488A (es) Anticuerpos dirigidos al receptor de factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3
EP3047619A4 (en) Wake-up receiver with automatic interference rejection
EP3022157A4 (en) Stable salt-free polyaluminum chlorosulfates
GB2530988B (en) Monolithically integrated thin-film electronic conversion unit for lateral multifunction thin-film solar cells
ZA201602232B (en) Spectrophotometer for the characterisation of receivers of solar collectors
GB2519659B (en) Drinks Carrier With Deformable Support Holes
UY34535A (es) Nuevo uso terapéutico de antagonistas del receptor p75.
ZA201507238B (en) Concentrating central solar receiver
CA2854747A1 (en) Trousers with integrated bowl
IN2012CH02984A (es)
UA59798U (ru) Применение сиропа амкесола как вещества с бронхолитической активностью